Clinical pharmacokinetics and pharmacodynamics of ramucirumab in the treatment of colorectal cancer

Expert Opinion on Drug Metabolism & Toxicology
Valentina GambardellaAndrés Cervantes

Abstract

Colorectal cancer is the third most common cancer worldwide. The prognosis of colorectal cancer patients still remains dismal and half of them will develop metastatic disease. Angiogenesis plays an essential role in colorectal tumorigenesis, and the VEGF pathway is one of the targets that has been validated up to now. The use of antiangiogenics along with chemotherapy has become an accepted standard for colorectal cancer. This review discusses the efficacy and safety profile of ramucirumab, a fully human immunoglobulin G1 monoclonal antibody against the vascular endothelial growth factor receptor-2 (VEGFR-2), for the treatment of second-line metastatic colorectal cancer upon progression to first-line chemotherapy including anti-angiogenics. Ramucirumab in combination with chemotherapy represents a valid option in second-line treatment of advanced colorectal cancer patients, who progressed on previous bevacizumab-based combinations. This agent demonstrates a similar benefit in terms of overall survival to other angiogenesis inhibitors (bevacizumab and ziv-aflibercept) used in this setting.

References

Oct 3, 2002·Nature Reviews. Cancer·Napoleone Ferrara
Jun 5, 2003·Nature Medicine·Napoleone FerraraJennifer LeCouter
Jun 18, 2003·The Journal of Cell Biology·Holger GerhardtChrister Betsholtz
Dec 9, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Daniel J Hicklin, Lee M Ellis
May 10, 2006·Biochemical and Biophysical Research Communications·Hua-Quan MiaoZhenping Zhu
Apr 20, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bruce J GiantonioUNKNOWN Eastern Cooperative Oncology Group Study E3200
May 24, 2007·British Journal of Cancer·T Kamba, D M McDonald
May 25, 2007·Nature Reviews. Cancer·Henk M W Verheul, Herbert M Pinedo
Jul 13, 2007·Critical Reviews in Oncology/hematology·Charlotte Magdelaine-BeuzelinHervé Watier
Sep 19, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Hagop YoussoufianEric K Rowinsky
Apr 19, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Leonard B SaltzJim Cassidy
Dec 17, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Scott KopetzJohn V Heymach
Jan 6, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jennifer L SpratlinS Gail Eckhardt
Aug 11, 2011·Structure·Matthew C FranklinPaul Kussie
Mar 7, 2012·The Journal of Experimental Medicine·Petra HamerlikJiri Bartek
Nov 22, 2012·The Lancet Oncology·Jaafar BennounaUNKNOWN ML18147 Study Investigators
Jun 28, 2013·Expert Opinion on Biological Therapy·Jeffrey Melson Clarke, Herbert I Hurwitz
Oct 4, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Andrew X ZhuKeith Stuart
Sep 6, 2014·Annals of Oncology : Official Journal of the European Society for Medical Oncology·E Van CutsemUNKNOWN ESMO Guidelines Working Group
Dec 17, 2014·Immunotherapy·Elizabeth C SmythIan Chau

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Related Concepts

Related Feeds

Angiogenesis Inhibitors to Treat Cancer

Cancer treatments including angiogenesis inhibitors prevent tumor cells from receiving nutrients and oxygen. Here is the latest research on angiogenesis inhibitors for the treatment of cancer.

Cell Signaling by Tyrosine Kinases

Receptor tyrosine kinases (RTKs) are the high-affinity cell surface receptors for many polypeptide growth factors, cytokines, and hormones. RTKs have been shown not only to be key regulators of normal cellular processes but also to have a critical role in the development and progression of many types of cancer. Discover the latest research on cell signaling and RTK here.

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.

© 2022 Meta ULC. All rights reserved